Clinical trials: Classification
Carcinoma, Small Cell Lung
Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG
This trial is designed to test the impact of adjuvant BEC2 (2.5 mg)/BCG vaccination on survival in patients with LD Small Cell Lung Cancer (SCLC).
- Trial name
- NCT00037713
- Testing
- BEC2 Vaccine
- Volunteers
- 515 people
- Sponsor
- Eli Lilly and Company
Myelodysplastic Syndrome, MDS
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
The primary objectives of this study are to determine if rigosertib sodium, given orally in the form of soft gel capsules, is safe and is associated with a reduction in the number of blood transfusion units that are needed in…
- Conditions
- Myelodysplastic Syndrome, MDS, Trisomy 8
- Trial name
- ONTARGET (NCT01584531)
- Testing
- rigosertib
- Where
- 5 sites in United States
- Volunteers
- 82 people
- Sponsor
- Traws Pharma, Inc.
Prostate Cancer
Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer
The goal of this clinical trial is to test if the experimental agent accurately determines the aggressiveness of prostate cancer (biopsy-verified ISUP grade).
- Trial name
- uTRACE-101 (NCT06474806)
- Testing
- 64Cu-DOTA-AE105
- Where
- 9 sites in Denmark, Germany and 1 more
- Volunteers
- 168 people
- Sponsor
- Curasight
Small Cell Lung Carcinoma
A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.
The purpose of this study is to evaluate the effect of hepatic impairment on the systemic pharmacokinetics (PK), safety, and tolerability of JDQ443 in participants with varying degrees of hepatic impairment.
- Trial name
- NCT05329623
- Testing
- JDQ443
- Where
- 2 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Early Gastric Cancer
A Clinical Trial to Evaluate the Sensitivity and Specificity of "WAYMED Endo" Compared to the Endoscopists in Classifying Early Gastric Cancer (EGC) Based on the Depth of Invasion in Endoscopic Images
The purpose of this clinical trial is to prove that the prediction capability of 'WAYMED endo' is superior to that of the endoscopists in classifying EGC based on the depth of invasion categories in gastro-endoscopic images.
- Trial name
- NCT06317103
- Testing
- WADYMED endo, Control group (the endoscopists)
- Where
- South Korea
- Volunteers
- 653 people
- Sponsor
- WAYCEN Inc
Breast Cancer
TRACE4BUS for BI-RADS Classification
The purpose of this clinical study is to evaluate the use of the TRACE4BUS software that is proposed to support the physician in reporting the results of breast ultrasound according to the international classification standard…
- Trial name
- NCT06920108
- Where
- Italy
- Volunteers
- 590 people
- Sponsor
- DeepTrace Technologies S.r.l.
Ventricular Dysfunction, Left, Ventricular Function, Left
Federated Learning for Point-of-Care Cardiac Ultrasound
This prospective, multicenter study will evaluate a federated machine-learning system designed to analyze focused cardiac point-of-care ultrasound examinations.
- Conditions
- Ventricular Dysfunction, Left, Ventricular Function, Left, Echocardiography, Ultrasonography
- Trial name
- FL-POCUS (NCT07800962)
- Testing
- Focused Cardiac Point-of-Care Ultrasonography, FL-POCUS Federated Machine-Learning Analysis System
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- Truway Health, Inc.
COVID-19, Coronavirus Infections
Audio Data Collection for Identification and Classification of Coughing
An open access study that will define and collect digital measures of coughing in multiple populations and public spaces using various means of audio data collection.
- Conditions
- COVID-19, Coronavirus Infections, Hay Fever, Asthma
- Trial name
- NCT04326309
- Where
- United States
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- HealthMode Inc.
Hepatic Insufficiency
A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems
This study is open to adults aged 18 years and older. People without liver problems and people who have mild or moderate liver problems can join the study.
- Trial name
- NCT05661344
- Testing
- BI 1015550
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Degenerative Osteoarthritis, Rheumatoid Arthritis
All Polyethylene Tibia-VEGA Kiel
Obligatory Post-Marketing Clinical Follow-up (PMCF) as part of the post marketing surveillance plan for the product under investigation For this PMCF only CE-marked medical devices will be used within their intended purpose and…
- Conditions
- Degenerative Osteoarthritis, Rheumatoid Arthritis, Post-traumatic; Arthrosis, Other Instability, Knee
- Trial name
- APT-VEGA_KI (NCT02756702)
- Testing
- All-Poly
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Aesculap AG
Psoriasis
A Randomized, Open, Parallel, Controlled, Multi-center, Interventional, Cross-sectional Study to Evaluate the Detection Rate of Psoriatic Arthritis in Korean Moderate-to-severe Psoriasis Patients, With or Without Active Screening for Arthritis in Psoriasis (ASAP Study)
This was a randomized, open, parallel, controlled, multi-center, interventional, cross-sectional study to evaluate the detection rate of Psoriatic arthritis (PsA) in Korean moderate to severe Psoriasis (PsO) patients with or…
- Trial name
- ASAP (NCT05758402)
- Testing
- Routine practice group, EARP group
- Where
- 15 sites in South Korea
- Volunteers
- 368 people
- Sponsor
- Novartis Pharmaceuticals
Healthy, Liver Diseases
Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
The main objective of this study was to investigate the influence of mild and moderate liver impairment on the pharmacokinetics, safety and selected pharmacodynamic parameters of BI 1744 CL in comparison to a control group with…
- Trial name
- NCT02171832
- Testing
- BI 1744 CL, low dose, BI 1744 CL, high dose
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Cardiac Arrythmias, Valve Heart Disease
FRAILTY Classification Algorithm for the Corsano CARDIOWATCH 287-2: a Development and Validation Study
The FRAILTY-CARDIOWATCH study is investigating how well the Corsano CardioWatch 287-2, a wrist-worn medical device, can classify frailty in patients.
- Conditions
- Cardiac Arrythmias, Valve Heart Disease, Cardiac Ischemia
- Trial name
- FRAILTY-CW2 (NCT06930833)
- Testing
- Corsano CardioWatch 287-2
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Corsano Health B.V.
Dyslipidemias
Evaluation of Dyslipidemia Management After Statin and Ezetimibe Complex Treatment
This study is a large-scale, prospective, multi-site, and non-interventional observational study to observe the change and safety of dyslipidemia management status when administering statin+etimib complex drugs in patients with…
- Trial name
- NCT05614765
- Testing
- Statin+Ezetimibe compound
- Where
- South Korea
- Volunteers
- 18,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Breast Cancer
The ABC Study: Assessment of Breast Density Classification
The MARIA® breast imaging system is a CE-marked radiofrequency (RF) medical imaging device. The system employs an electromagnetic imaging technique that exploits the dielectric contrast between normal and cancerous tissues.
- Trial name
- NCT04882306
- Testing
- Bilateral MARIA scan
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- Micrima, Ltd.
Cellular Diagnosis, Prostate Cancer
ClariCore Optical Biopsy System Used in TRUS (Trans-Rectal Ultrasound)-Guided Prostrate Biopsy
The purpose of the study is to collect information on prostrate biopsy tissue for use in developing a method determining the difference in normal and cancerous prostrate tissue using the ClariCore System.
- Trial name
- NCT02928640
- Testing
- ClariCore System
- Where
- 5 sites in United States
- Volunteers
- 200 people
- Sponsor
- Precision Biopsy, Inc.
Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases
The primary objective was to evaluate the safety of CD7 CAR-T cells for the treatment of subjects with relapsed/refractory AID. CD7 CAR-T cells were infused in a single infusion in subjects who were screened after signing an…
- Trial name
- NCT06871644
- Testing
- T cell injection targeting CD7 chimeric antigen receptor
- Where
- China
- Volunteers
- 18 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
ITCH, Atopic Dermatitis
Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.
This study is being done to obtain descriptive classifications of pruritus using a patient directed survey system and assess change in pruritus over time in patients with Atopic Dermatitis over 4 weeks with use of topical…
- Trial name
- NCT07560618
- Testing
- Roflumilast Cream 0.15%
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Integrative Skin Science and Research
Concussion, Mild, Concussion; Eye
EYE-SYNC Concussion Classification Study
The purpose of this study is to determine the sensitivity and specificity of an aid in assessment of concussion based on eye-tracking, in comparison to a clinical reference standard appropriate for sport-related concussion…
- Conditions
- Concussion, Mild, Concussion; Eye, Concussion, Brain, Concussion, Severe
- Trial name
- NCT04381767
- Testing
- EYE-SYNC
- Where
- United States
- Volunteers
- 1,303 people
- Sponsor
- Sync-Think, Inc.
Liver Diseases, Healthy
A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems
This study is open to adults between 18 and 80 years of age. People with a body mass index (BMI) between 18 and 42 kg/m^2 can take part. Women can only participate if they cannot get pregnant.
- Trial name
- NCT06692322
- Testing
- Zongertinib (BI 1810631)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Boehringer Ingelheim